Nexentis Technologies issues going-concern warning
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Nexentis Technologies Inc. (NXTS) reported a net loss of $12.730 million for the nine months ended September 30, 2026, versus $5.395 million a year earlier. Its continuing biotechnology and renewable-energy segments reported no revenue for the period; operating loss was $11.335 million, including a noncash $6.291 million goodwill impairment at MitoCareX.
Third-quarter net gain was $5.019 million, compared with $370,000 a year earlier, while operating loss was $1.234 million. Financing income was $7.067 million for the quarter, versus $174,000 a year earlier. Nine-month operating cash outflow was $3.186 million, compared with $2.311 million.
At September 30, cash and equivalents were $2.837 million and short-term bank deposits were $3.324 million. Management said existing cash would not fund operations for the 12 months following issuance, creating substantial doubt about the company’s ability to continue as a going concern. It plans to seek equity financing or strategic-partnership capital, which may not be available. The Save Foods sale generated an $898,000 gain on deconsolidation.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointThird-quarter net gain was $5.019 million, versus $370,000 a year earlier.
- Minor pointSave Foods deconsolidation produced a $898,000 gain.
Negative
- Major pointNine-month net loss widened to $12.730 million from $5.395 million.
- Major point. Forward-looking: it has not happened yet and may not happen.Management projects existing cash will not fund operations for the next 12 months.
- Moderate pointOperating cash outflow reached $3.186 million, versus $2.311 million.
- Minor pointMitoCareX goodwill impairment was $6.291 million.
Filing Explained
The October twenty-six consulting-share issuance reduced existing holders’ percentage ownership, absent offsetting changes.
The filing reports that Nexentis completed a one-for-five reverse split on
Separately, a lender exercised part of its warrants on
Key Figures
Key Terms
substantial doubt financial
goodwill impairment financial
discontinued operations financial
fair value option financial
Level 3 technical
contingent consideration financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did NXTS lose in the first nine months of 2026?
What were NXTS's third-quarter 2026 net gain and operating loss?
What does NXTS say about its ability to fund operations?
How much goodwill did NXTS impair, and which business was affected?
What did NXTS receive in the Save Foods sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For
the quarterly period ended
For the transition period from __________ to ____________
Commission
File No.
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| The
|
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| ☐ | Large accelerated filer | ☐ | Accelerated filer |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of November 16, 2026, the registrant had
Nexentis Technologies Inc.
Quarterly Report on Form 10-Q
TABLE OF CONTENTS
| Page | ||
| Forward-Looking Statements | 3 | |
| PART I - FINANCIAL INFORMATION | 4 | |
| Item 1. | Condensed Consolidated Interim Financial Statements (unaudited) | 4 |
| Condensed Consolidated Interim Balance Sheets (unaudited) | 6 | |
| Condensed Consolidated Interim Statements of Comprehensive Loss (unaudited) | 7 | |
| Condensed Consolidated Interim Statements of Stockholders’ Equity (unaudited) | 8 | |
| Condensed Consolidated Interim Statements of Cash Flows (unaudited) | 10 | |
| Notes to Condensed Consolidated Interim Financial Statements | 11 - 34 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 35 |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 45 |
| Item 4. | Controls and Procedures | 45 |
| PART II - OTHER INFORMATION | 46 | |
| Item 1 | Legal Proceedings | 46 |
| Item 1A. | Risk Factors | 46 |
| Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds | 46 |
| Item 3 | Defaults Upon Senior Securities | 46 |
| Item 4 | Mine Safety Disclosures | 46 |
| Item 5 | Other Information | 46 |
| Item 6. | Exhibits | 47 |
| SIGNATURES | 48 | |
| 2 |
FORWARD-LOOKING STATEMENTS
Certain information set forth in this Quarterly Report on Form 10-Q (the “Quarterly Report”) including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:
| ● | Our efforts to complete and integrate current and/or future acquisitions and joint ventures, which could disrupt our current business activities and adversely affect our results of operations or future growth; |
| ● | Regulatory and compliance changes may adversely impact Solterra’s operations and our joint venture value; |
| ● | Joint venture and partnership risks may affect Solterra’s projects and our joint venture value; |
| ● | Our ability to successfully develop and commercialize MitoCareX’s products and obtain required regulatory approvals; |
| ● | Our ability to continue as a going concern and to obtain the additional capital required to fund our operations and MitoCareX’s development programs; |
| ● | Operational and business opportunities available to us following the acquisition of MitoCareX;
|
| ● | Our relationships with third parties, including those that support MitoCareX’s operations; |
| ● | International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States or Israel; |
| ● | The evolution of our business strategy may not be successful and we may require additional financing, have increased operational costs or experience other financial harm to our business and financial condition; |
| ● | The effects of geopolitical events, including instability or the escalation of armed conflicts in the Middle East, including the security situation in Israel; |
| ● | Our ability to attract and retain sufficient, qualified personnel; |
| ● | Our ability to obtain or maintain patents or other appropriate protection for the intellectual property; |
| ● | Our ability to adequately support future growth; |
| ● | Potential product liability or intellectual property infringement claims; |
| ● | Portfolio concentration; |
| ● | Our ability to regain and maintain compliance with the continued listing requirements of the Nasdaq Capital Market; |
| ● | The market price of our common stock; |
| ● | International expansion of our business and operations; and |
| ● | Information with respect to any other plans and strategies for our business. |
These statements are only predictions and involve known and unknown risks, uncertainties and other factors. Readers are urged to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (the “SEC”). We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.
As used in this Quarterly Report and unless otherwise indicated, the terms “Nexentis,” “we,” “us,” “our,” or “our company” refer to Nexentis Technologies Inc., and MitoCareX Bio Ltd., our wholly owned subsidiary (“MitoCareX”) and our wholly owned subsidiary, NITO Renewable Energy, Inc. (“NITO Renewable”), which owns 70% of SB Storage 1 S.R.L.
| 3 |
PART I FINANCIAL INFORMATION
Item 1. Financial Statements
NEXENTIS TECHNOLOGIES INC.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
AS OF SEPTEMBER 30, 2026
| 4 |
NEXENTIS TECHNOLOGIES INC.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
AS OF SEPTEMBER 30, 2026
USD IN THOUSANDS
TABLE OF CONTENTS
| Page | |
| CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED): | |
| Condensed Consolidated Interim Balance Sheets (unaudited) | 6 |
| Condensed Consolidated Interim Statements of Comprehensive Loss (unaudited) | 7 |
| Condensed Consolidated Interim Statements of Stockholders’ Equity (unaudited) | 8 |
| Condensed Consolidated Interim Statements of Cash Flows (unaudited) | 10 |
| Notes to Condensed Consolidated Interim Financial Statements | 11 - 34 |
| 5 |
NEXENTIS TECHNOLOGIES INC.
UNAUDITED CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS
(USD in thousands except share and per share data)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Unaudited | Audited | |||||||
| A s s e t s | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | ||||||||
| Short term bank deposits | - | |||||||
| Restricted cash | ||||||||
| Investment in marketable securities (Notes 5(2), 7) | ||||||||
| Accounts receivable | - | |||||||
| Short term loan (Note 5(1)) | - | |||||||
| Prepaid expenses | ||||||||
| Other current assets | ||||||||
| Assets held for sale | - | |||||||
| T o t a l Current assets | ||||||||
| Long term prepaid expenses | ||||||||
| Right-of-use asset arising from operating leases | ||||||||
| Property and equipment, net | ||||||||
| Investment in Solar Photovoltaic joint venture project (Note 6) | ||||||||
| Investment in solar projects under development | ||||||||
| Goodwill (Note 4) | - | |||||||
| Intangible asset (Note 3) | ||||||||
| T o t a l assets | ||||||||
| Liabilities and Shareholders’ Equity | ||||||||
| Current Liabilities | ||||||||
| Short term loan (Note 10 (2)) | - | |||||||
| Credit facility (Note 9) | - | |||||||
| Accounts payable | ||||||||
| Other payable and accrued expenses (Note 3) | ||||||||
| Current warrant liability (Note 9) | - | |||||||
| Liabilities held for sale | - | |||||||
| T o t a l current liabilities | ||||||||
| Non-current operating lease liabilities | ||||||||
| Credit facility | - | |||||||
| Stock purchase warrants liabilities (Note 10(1)) | ||||||||
| Contingent consideration (Note 3) | ||||||||
| Deferred taxes liability | ||||||||
| T o t a l liabilities | ||||||||
| Stockholders’ Equity (**) | ||||||||
| Common stock, $ | -* | -* | ||||||
| Preferred stock, $ | - | - | ||||||
| Additional paid-in capital (**) | ||||||||
| Foreign currency translation adjustments (**) | ( | ) | ( | ) | ||||
| Accumulated deficit (**) | ( | ) | ( | ) | ||||
| T o t a l Company’s stockholders’ equity (**) | ||||||||
| Non-controlling interests (**) | ( | ) | ( | ) | ||||
| T o t a l stockholders’ equity (**) | ||||||||
| T o t a l liabilities and stockholders’ equity (**) | ||||||||
| (*) |
| (**) |
The accompanying notes are an integral part of the condensed consolidated interim financial statements.
| 6 |
NEXENTIS TECHNOLOGIES INC.
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE GAIN (LOSS)
(USD in thousands except share and per share data)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Nine months ended | Three months ended | |||||||||||||||
| September 30 | September 30 | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development expenses | ( | ) | - | ( | ) | - | ||||||||||
| General and administrative expenses, exclusive of depreciation and amortization | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Change in fair value of contingent consideration | - | - | ||||||||||||||
| Goodwill impairment | ( | ) | - | - | - | |||||||||||
| Depreciation and amortization | ( | ) | - | ( | ) | - | ||||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Financing income (expense), net | ( | ) | ( | ) | ||||||||||||
| Other income | - | |||||||||||||||
| Changes in fair value of investments measured under the fair value option (Notes 5, 6, 7) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net gain (loss) before tax | ( | ) | ( | ) | ||||||||||||
| Income taxes | - | - | ||||||||||||||
| Net gain (loss) from continuing operation | ( | ) | ( | ) | ||||||||||||
| Net gain (loss) from discontinued operations (Note 8) | ( | ) | ( | ) | ||||||||||||
Net gain (loss) | ( | ) | ( | ) | ||||||||||||
| Less: Net loss attributable to non-controlling interests | ||||||||||||||||
| Net gain (loss) attributable to the Company’s stockholders’ equity | ( | ) | ( | ) | ||||||||||||
| Loss per share from continuing operations (basic) (*) | ( | ) | ( | ) | ||||||||||||
| Gain (loss) per share from discontinued operations (basic) (*) | ( | ) | ( | ) | ||||||||||||
| Total gain (loss) per share (basic) | ( | ) | ( | ) | ||||||||||||
| Weighted average number of shares of Common Stock outstanding - basic (*) | ||||||||||||||||
| Gain (loss) per share from continuing operations (diluted) (*) | ( | ) | ( | ) | ( | ) | ||||||||||
| Gain (loss) per share from discontinued operations (diluted) (*) | ( | ) | ( | ) | ||||||||||||
| Total Gain (loss) per share (diluted) | ( | ) | ( | ) | ( | ) | ||||||||||
| Weighted average number of shares of Common Stock outstanding – diluted (*) | ||||||||||||||||
| Comprehensive income (loss): | ||||||||||||||||
| Net income (loss) | ( | ) | ( | ) | ||||||||||||
| Comprehensive income (loss) - Foreign currency translation adjustments | ( | ) | ( | ) | ||||||||||||
| Comprehensive income (loss) | ( | ) | ( | ) | ||||||||||||
| Other comprehensive income (loss) attributable to non-controlling interests | ||||||||||||||||
| Comprehensive income (loss) attributable to the Company’s stockholders | ( | ) | ( | ) | ||||||||||||
| (*) |
The accompanying notes are an integral part of the condensed consolidated interim financial statements.
| 7 |
NEXENTIS TECHNOLOGIES INC.
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(USD in thousands, except share and per share data)
| Foreign | Total | |||||||||||||||||||||||||||||||
| Number | Additional | currency | Company’s | Non- | ||||||||||||||||||||||||||||
| of shares | paid-in | translation | Accumulated | stockholders’ | controlling | Total | ||||||||||||||||||||||||||
| (**) | Amount | capital | adjustments | deficit | equity | interests | equity | |||||||||||||||||||||||||
| BALANCE AT DECEMBER 31, 2025 | -* | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Issuance of shares (Note 10(2)) | -* | - | - | - | ||||||||||||||||||||||||||||
| Issuance of shares for services | -* | - | - | - | ||||||||||||||||||||||||||||
| Share based compensation | - | - | - | - | -* | |||||||||||||||||||||||||||
| Deconsolidation of Save Foods Ltd | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Foreign currency translation adjustments | - | - | - | - | ||||||||||||||||||||||||||||
| Net loss for the period | - | - | - | - | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| BALANCE AT MARCH 31, 2026 | -* | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Issuance of shares (Note 10(6)) | -* | - | - | - | -* | - | -* | |||||||||||||||||||||||||
| Issuance of shares (Note 10(7)) | -* | - | - | - | -* | - | -* | |||||||||||||||||||||||||
| Share based compensation | - | - | - | - | - | |||||||||||||||||||||||||||
| Capital contribution from non-controlling interests | - | - | - | - | ||||||||||||||||||||||||||||
| Foreign currency translation adjustments | - | - | - | - | ||||||||||||||||||||||||||||
| Net loss for the period | - | - | - | - | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| BALANCE AT JUNE 30, 2026 | -* | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Issuance of shares upon achievement of contingent consideration milestone (Note 3) | -* | - | - | - | ||||||||||||||||||||||||||||
| Share based compensation | - | - | - | - | - | |||||||||||||||||||||||||||
| Reclassification of warrants liabilities into equity (Notes 9, 10(6) and 10(7)) | - | - | - | - | - | |||||||||||||||||||||||||||
| Foreign currency translation adjustments | - | - | - | - | ||||||||||||||||||||||||||||
| net gain for the period | - | - | - | - | ( | ) | ||||||||||||||||||||||||||
| BALANCE AT SEPTEMBER 30, 2026 | -* | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| 8 |
NEXENTIS TECHNOLOGIES INC.
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(USD in thousands, except share and per share data)
| Foreign | Total | |||||||||||||||||||||||||||||||
| Number | Additional | currency | Company’s | Non- | ||||||||||||||||||||||||||||
| of shares | paid-in | translation | Accumulated | stockholders’ | controlling | Total | ||||||||||||||||||||||||||
| (**) | Amount | capital | adjustments | deficit | equity | interests | equity | |||||||||||||||||||||||||
| BALANCE AT DECEMBER 31, 2024 | -* | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Issuance of shares for private investment in public equity (PIPE) agreement | -* | - | - | - | ||||||||||||||||||||||||||||
| Warrant exercises | -* | - | - | - | ||||||||||||||||||||||||||||
| Share based compensation | - | - | -* | - | - | -* | -* | -* | ||||||||||||||||||||||||
| Foreign currency translation adjustments | - | - | - | ( | ) | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Net loss for the period | - | - | - | - | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| BALANCE AT MARCH 31, 2025 | -* | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Issuance of shares for services | -* | - | - | - | ||||||||||||||||||||||||||||
| Issuance of shares for purchase agreement | -* | - | - | - | ||||||||||||||||||||||||||||
| Warrant exercises | -* | - | - | - | ||||||||||||||||||||||||||||
| Share based compensation | - | - | -* | - | - | -* | -* | -* | ||||||||||||||||||||||||
| Foreign currency translation adjustments | - | - | - | ( | ) | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Deconsolidation of NTWO OFF Ltd | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Net loss for the period | - | - | - | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||
| BALANCE AT JUNE 30, 2025 | -* | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| BALANCE | -* | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Issuance of shares for services | -* | - | - | - | ||||||||||||||||||||||||||||
| Issuance of shares for purchase agreement | -* | - | - | - | ||||||||||||||||||||||||||||
| Warrant exercises | -* | - | - | - | ||||||||||||||||||||||||||||
| Capital contribution from non-controlling interests | - | - | - | - | ||||||||||||||||||||||||||||
| Commitment to issue shares | - | - | - | - | - | |||||||||||||||||||||||||||
| Share based compensation | - | - | -* | - | - | -* | -* | -* | ||||||||||||||||||||||||
| Foreign currency translation adjustments | - | - | - | ( | ) | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Net gain for the period | - | - | - | - | ( | ) | ||||||||||||||||||||||||||
| BALANCE AT SEPTEMBER 30, 2025 | -* | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| BALANCE | -* | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| (*) |
| (**) |
The accompanying notes are an integral part of the condensed consolidated interim financial statements.
| 9 |
NEXENTIS TECHNOLOGIES INC.
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
(USD in thousands except share and per share data)
| 2026 | 2025 | |||||||
| Nine months ended | ||||||||
| September 30 | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | ( | ) | ( | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating: | ||||||||
| Depreciation and amortization | ||||||||
| Deferred income taxes | ( | ) | - | |||||
| Issuance of shares to employees and service providers | ||||||||
| Share-based compensation to employees and directors | ||||||||
| Gain from sales of property and equipment | - | ( | ) | |||||
| Expenses funded by non-controlling interests | ||||||||
| Gain from standby equity purchase agreement II | ( | ) | ( | ) | ||||
| Expenses from standby equity purchase agreement II | - | |||||||
| Interest in respect of loans | ||||||||
| Gain from deconsolidation of subsidiary | ( | ) | ( | ) | ||||
| Goodwill impairment | - | |||||||
| Accrued interest income on short-term bank deposits | ( | ) | - | |||||
| Change in fair value of non-current warrant liability | ( | ) | ||||||
| Change in fair value of credit facility | ||||||||
| Change in fair value of stock purchase warrant liabilities | ( | ) | ||||||
| Change in fair value of investment in nonconsolidated affiliate | - | |||||||
| Change in fair value of short-term loan | ( | ) | ||||||
| Change in fair value of long-term loan | - | ( | ) | |||||
| Change in fair value of Solar Photovoltaic joint venture project | ( | ) | ||||||
| Change in fair value of investment in marketable securities | ||||||||
| Change in fair value of contingent consideration | ( | ) | - | |||||
| Decrease (increase) in accounts receivable | ||||||||
| Decrease (increase) in inventory | ( | ) | ||||||
| Decrease (increase) in prepaid expenses and other current assets | ( | ) | ||||||
| Increase (decrease) in accounts payable | ( | ) | ||||||
| Increase in other payables and accrued expenses | ||||||||
| Decrease in operating lease expense | ||||||||
| Change in operating lease liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Investment in short-term bank deposits | ( | ) | - | |||||
| Investment in solar projects under development | ( | ) | ( | ) | ||||
| Purchase of property | ( | ) | - | |||||
| Proceeds from sales of property and equipment | - | |||||||
| Cash and cash equivalents deconsolidated upon loss of control (Note 8) | ( | ) | ( | ) | ||||
| Short term loan granted | - | ( | ) | |||||
| Proceeds from repayments of loans related to Solar Photovoltaic projects | - | |||||||
| Loan to Solar Photovoltaic joint venture project | ( | ) | ( | ) | ||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from credit facility | - | |||||||
| Repayment of credit facility | - | ( | ) | |||||
| Proceeds from issuance of shares and warrants | ||||||||
| Proceeds from exercise of warrants | - | |||||||
| Proceeds from promissory note | - | |||||||
| Payment of contingent consideration | ( | ) | - | |||||
| Repayments of short-term loan | ( | ) | - | |||||
| Net proceeds from issuance of shares pursuant to Purchase Agreement | ||||||||
| Net cash provided by financing activities | ||||||||
| Effect of exchange rate changes on cash and cash equivalents | ( | ) | ||||||
| INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | ( | ) | ||||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD | ||||||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD | ||||||||
| Cash paid during the period for: | ||||||||
| Interest | ||||||||
| Non cash transactions: | ||||||||
| Initial recognition of operating lease liability and a corresponding right-of- use asset | - | |||||||
| Reclassification of warrant liabilities to equity upon exercise of warrants | - | |||||||
| Issuance of shares for future credit line | - | |||||||
| Non-cash financing costs related to issuance of promissory note | - | |||||||
| Reclassification of contingent cash consideration to accrued expenses | - | |||||||
| Reclassification of warrant liabilities into equity | - | |||||||
| Issuance of shares upon achievement of contingent consideration milestone | - | |||||||
| Issuance of shares for future services | - | |||||||
| Investment in marketable securities in exchange for shares of a subsidiary | - | |||||||
The accompanying notes are an integral part of the condensed consolidated interim financial statements
| 10 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 1 – GENERAL
| A. | Operations |
Nexentis Technologies Inc. (formerly N2OFF, Inc.) (the “Company”) was incorporated on April 1, 2009, under the laws of the State of Delaware. On November 6, 2023, the Company was reincorporated into the State of Nevada. The Company’s Common Stock is listed on the Nasdaq Capital Market under the symbol “NXTS”.
The Company is engaged in renewable energy projects through its wholly owned subsidiary NITO Renewable Energy Inc., which was incorporated in the State of Nevada on February 10, 2025. The Company is also engaged in pharmaceuticals operations for the development of targeted cancer therapeutics for Non-Small Cell Lung Cancer, through its wholly-owned subsidiary MitoCareX Bio Ltd. (“MitoCareX”), a private entity incorporated in the State of Israel acquired by the Company on October 20, 2025.
Under
its renewable energy operations, on February 24, 2025, the Company entered into a shareholders agreement with Solterra Brand Services
Italy SRL (“SB”) and SB Impact 4 LTD (which on April 14, 2025 changed its name to SB Storage 1 S.R.L), a wholly owned subsidiary
of SB (“SBI4”) pursuant to which the Company purchased, through its subsidiary NITO Renewable Energy Inc.,
Additionally,
through its
| B. | Reverse stock split |
On April 8, 2026, the Company effected a 1-for-7 reverse stock split of the Company’s outstanding Common Stock (the “April Reverse Stock Split”).
As a result of the April Reverse Stock Split, every seven shares of the Company’s outstanding Common Stock prior to the effect of that amendment were combined and reclassified into one share of the Company’s Common Stock. No fractional shares were issued in connection with or following the reverse split and the shares were rounded to the nearest whole number. The authorized capital and par value of the Common Stock remained unchanged.
On November 9, 2026, subsequent to the balance sheet date and prior to the issuance of these condensed consolidated financial statements, the Company effected an additional 1-for-5 reverse stock split of its outstanding Common Stock (the “November Reverse Stock Split”). As a result, every five shares of the Company’s outstanding Common Stock were combined and reclassified into one share of Common Stock.
All shares, stock options, warrants and per share information in these condensed consolidated financial statements have been retrospectively adjusted to reflect the effects of both reverse stock splits on a retroactive basis.
| 11 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 1 – GENERAL (continued)
| C. | Going concern uncertainty |
Since
inception, the Company has incurred significant losses and negative cash flows from operations and has an accumulated deficit of $
The Company’s management expects that the Company will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected cash flows and cash balances as of September 30, 2026, management currently is of the opinion that its existing cash will not be sufficient to fund its operations during the twelve months following the date of issuance of these financial statements. As a result, there is substantial doubt regarding the Company’s ability to continue as a going concern.
Management plans to continue securing sufficient financing through the sale of additional equity securities or capital inflows from strategic partnerships. However, additional funds may not be available when the Company needs them, on favorable terms, or at all. If the Company is unsuccessful in securing sufficient financing, it may need to cease operations.
The financial statements do not include adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern.
| D. | Israel –war |
On February 28, 2026, the United States and Israel preemptively attacked Iran to eliminate its nuclear and ballistic missile capabilities. As part of this conflict, Iran launched missile and drone attacks toward population centers and military installations in Israel, Europe and neighboring countries in the Gulf region, and also launched counter strikes against U.S. forces and allied bases throughout the Gulf region. These events have resulted in civilian casualties and property damage in Israel. In early March 2026, Hezbollah joined the conflict and carried out missile attacks against Israel, leading to Israeli retaliatory strikes and an extended ground incursion, with Israeli forces occupying a zone approximately 10 kilometers deep in southern Lebanon. While temporary ceasefires between the United States, Israel, and Iran, and between Israel and Lebanon, were reached in April 2026, hostilities between Israel and Hezbollah remain ongoing with occasional flare ups between the United States and Iran, there can be no assurance that the temporary ceasefires will be upheld or that a permanent ceasefire will be reached, and the situation remains volatile and highly unstable.
As a significant portion of the Company’s activities, including research and development activities conducted through MitoCareX, are located in Israel, and members of the Company’s management and certain employees and consultants are located in Israel, the Company’s operations may be affected by economic, political, geopolitical and military conditions affecting Israel. Any escalation or expansion of the war could have a negative impact on both global and regional conditions and may adversely affect the Company’s business, financial condition, and results of operations.
The Company is unable to predict the duration or severity of the current conflict or any potential escalation. To date, the conflict has resulted primarily in certain delays in the Company’s research and development activities, including activities conducted by MitoCareX. The Company is continuing to regularly follow developments on the matter and is examining the effects on its operations and the value of its assets.
| 12 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION
Basis of presentation
The condensed interim consolidated financial statements included in this Quarterly Report are unaudited. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company’s financial position as of September 30, 2026, and its results of operations, changes in stockholders’ equity, and cash flows for the nine and three months ended September 30, 2026 and 2025. The results of operations for the nine and three months ended September 30, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 31, 2026. The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2025 included in such Form 10-K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies.
Use of Estimates
The preparation of unaudited condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to impairment assessment of intangible assets and goodwill and calculation of fair value of the financial instruments. A change in estimates, including a change in the overall market value of the Company, could require reassessments of the items noted above.
Principles of consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. During the nine months ended September 30, 2026, the Company deconsolidated Save Foods Ltd. as of the date control was lost.
Short term bank deposits
Short term bank deposits consist of deposits held with financial institutions with original maturities of more than three months but not exceeding one year. These deposits are recorded at amortized cost, including accrued interest, which approximates their fair value due to their short-term maturities. Interest income is recognized as earned and included in financing expenses, net, in the consolidated interim statements of comprehensive gain (loss).
Discontinued operations
A component of an entity is identified as operations and cash flows that can be clearly distinguished, operationally and financially, from the rest of the entity. Under ASC 205-20, “Presentation of Financial Statements - Discontinued Operations” (“ASC 205-20”), a discontinued operation is a component of an entity that either has been disposed of, or is classified as held for sale and represents a strategic shift that has or will have a major effect on the entity’s operations and financial results, or a newly acquired business or nonprofit activity that upon acquisition is classified as held for sale. Discontinued operations are presented separately from continuing operations in the consolidated statements of Operations.
| 13 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continued)
Investment in equity securities
Investments in equity securities with readily determinable fair values, for which the Company does not have the ability to exercise significant influence over the investee, are accounted for in accordance with ASC 321, Investments—Equity Securities and are measured at fair value. Changes in fair value are recognized in the unaudited condensed consolidated statements of operations. Fair value is generally determined based on quoted market prices when available.
Goodwill and intangible asset
Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets acquired in business combinations accounted for in accordance with the “purchase method” and is allocated to reporting units at acquisition. Goodwill is not amortized but rather tested for impairment at least annually in accordance with the provisions of ASC Topic 350, “Intangibles - Goodwill and Other”. The Company performs its goodwill annual impairment test for the reporting units at December 31 of each year, or more often if indicators of impairment are present.
Intangible assets with finite lives are amortized using the straight-line basis over their useful lives, to reflect the pattern in which the economic benefits of the intangible assets are consumed or otherwise used up.
The evaluation of goodwill impairment and the determination of useful lives and amortization of intangible assets involves significant judgments and estimates, including assumptions related to future cash flows, discount rates and market conditions. The determination of the fair value of reporting units is inherently subjective, as it requires the use of valuation models and unobservable inputs. Accordingly, this assessment is considered a critical accounting estimate, and actual results may differ materially from those estimates.
As
of September 30, 2026, a non-cash goodwill impairment loss of $
Impairment of long-lived assets
Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Assets are categorized and evaluated for impairment at the lowest level of identifiable cash flows. In the event that the sum of the expected future undiscounted cash flows expected to be generated by the long-lived assets is less than the carrying amount of such assets, an impairment charge would be recognized and the assets would be written down to their estimated fair values. The Company did not record any impairment of long-lived assets for any of the periods presented.
Fair value
Fair value of certain of the Company’s financial instruments including cash, accounts payable, accrued expenses, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements” which defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements.
| 14 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continued)
Fair value (continued)
Fair value, as defined by ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise.
Valuation techniques are generally classified into three categories: (i) the market approach; (ii) the income approach; and (iii) the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs.
Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows:
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.
Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and
Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values.
Fair value measurements are required to be disclosed by the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), (ii) segregating those gains or losses included in earnings, and (iii) a description of where those gains or losses included in earning are reported in the statement of operations.
The Company’s financial assets that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows:
SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES ON RECURRING BASIS
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| As of September 30, 2026 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| US$ | ||||||||||||||||
| Assets: | ||||||||||||||||
| Investment in Solterra’s shares | - | - | ||||||||||||||
| Investment in Voice Assist’s shares | - | - | ||||||||||||||
| Loan to Solar Photovoltaic joint venture project | - | - | ||||||||||||||
| Total assets | - | |||||||||||||||
| 15 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continued)
Fair value (continued)
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| As of December 31, 2025 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| US$ | ||||||||||||||||
| Assets: | ||||||||||||||||
| Investment in Solterra’s shares | - | - | ||||||||||||||
| Loan to Solar Photovoltaic joint venture project | - | - | ||||||||||||||
| Convertible loan to Solterra | - | - | ||||||||||||||
| Total assets | - | |||||||||||||||
The following table presents the changes in fair value of the level 3 assets for the period from December 31, 2025 through September 30, 2026:
SCHEDULE OF FAIR VALUE OF THE LEVELS 3 ASSETS AND LIABILITIES
Loan to Solar photovoltaic joint venture project | Convertible loan to Solterra | Total | ||||||||||
| Assets: | ||||||||||||
| Outstanding at December 31, 2025 | ||||||||||||
| Additions during the period | - | |||||||||||
| Repayments during the period | ( | ) | ( | ) | ( | ) | ||||||
| Reclassification to other receivables upon settlement of loans | ( | ) | ( | ) | ( | ) | ||||||
| Changes in fair value | ( | ) | ( | ) | ||||||||
| Outstanding at September 30, 2026 | - | |||||||||||
The Company’s financial liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows:
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| As of September 30, 2026 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| US$ | ||||||||||||||||
| Liabilities: | ||||||||||||||||
| Contingent consideration | - | - | ||||||||||||||
| Stock purchase warrants liability | - | - | ||||||||||||||
| Credit facility | - | - | ||||||||||||||
| Total liabilities | - | - | ||||||||||||||
| 16 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continued)
Fair value (continued)
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| As of December 31, 2025 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| US$ | ||||||||||||||||
| Liabilities: | ||||||||||||||||
| Contingent consideration | - | - | ||||||||||||||
| Stock purchase warrants liability | - | - | ||||||||||||||
| Warrant liabilities to Pure Capital | - | - | ||||||||||||||
| Credit facility | - | - | ||||||||||||||
| Total liabilities | - | - | ||||||||||||||
The following table presents the changes in fair value of the level 3 liabilities for the period from December 31, 2025 through September 30, 2026:
Stock purchase warrants liability | Warrant liabilities to Pure Capital | Credit facility | Contingent consideration | Total | ||||||||||||||||
| US$ | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Outstanding at December 31, 2025 | ||||||||||||||||||||
| Reclassification of contingent consideration liabilities to other payables and accrued expenses | - | - | - | ( | ) | ( | ) | |||||||||||||
| Issuance of warrant liabilities | - | - | - | |||||||||||||||||
| Day-one loss on issuance of warrant liabilities | - | - | - | |||||||||||||||||
| Changes in fair value, including effect of warrant modification | - | - | - | |||||||||||||||||
| Reclassification of warrant liabilities to equity | ( | ) | ( | ) | - | - | ( | ) | ||||||||||||
| Issuance of shares upon achievement of contingent consideration milestone | - | - | - | ( | ) | ( | ) | |||||||||||||
| Changes in fair value | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
| Outstanding at September 30, 2026 | - | |||||||||||||||||||
| 17 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 3 – CONTINGENT CONSIDERATION AND INTANGIBLE ASSET
On October 20, 2025, the Company completed the acquisition of MitoCareX from SciSparc Ltd., Dr. Alon Silberman and Prof. Ciro Leonardo Pierri (collectively, the “Sellers”), which became a wholly-owned subsidiary of the Company. For additional information regarding the acquisition and the purchase price allocation, see Note 4 to the Company’s annual consolidated financial statements for the year ended December 31, 2025.
As
part of the consideration for the acquisition, the Sellers are entitled to receive additional shares of the Company’s Common Stock,
for no additional consideration, in an aggregate amount of up to
During
the nine months ended September 30, 2026, the first milestone was achieved, resulting in the Sellers becoming entitled to receive
The
Company concluded that the Contingent share consideration failed the indexation guidance of ASC 815-40 and accordingly this contingent
commitment to issue shares was classified as a liability. The liability is remeasured to fair value at each reporting date, with changes
in fair value recognized in the consolidated statements of operations. The Contingent share consideration was calculated as of September
30, 2026, at approximately $
Furthermore,
as additional consideration for the acquisition, the Sellers are entitled to receive, collectively,
During
the nine months ended September 30, 2026, financing transactions completed by the Company caused the maximum aggregate Contingent Cash
Consideration of $
| 18 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 4 – GOODWILL IMPAIRMENT ASSESSMENT
As of March 31, 2026, the Company performed an interim quantitative goodwill impairment analysis for the “MitoCareX” reporting unit, to which the Company’s goodwill is allocated, due to indicators identified during the period, including, among other things, a significant decline in the price of the Company’s Common Stock and corresponding market capitalization since the Company’s most recent goodwill impairment assessment, the Company’s market capitalization being below its stockholders’ equity, as well as increased uncertainty in the macroeconomic and geopolitical environment. Due to these indicators, the Company engaged a third-party valuation specialist to assist management in performing the quantitative goodwill impairment assessment as of March 31, 2026.
The quantitative assessment was performed by measuring the reporting unit’s fair value using the income approach, based on the expected present value of estimated future cash flows. The fair value measurement is categorized as Level 3 within the fair value hierarchy due to the use of unobservable inputs, such as financial projections, terminal growth rate, and discount rate. In applying the income approach, the Company evaluated the reasonableness of the inputs and outcomes of its discounted cash flow analysis against available market data. As part of this analysis, the Company concluded that the discount rate used in the current impairment analysis reflects higher market-based and MitoCareX-specific risk premiums, which are associated with changes in global macroeconomic conditions in 2026, including heightened geopolitical risks related to operations in the Middle East, particularly the conflict between Israel and Iran.
The
results of the impairment analysis indicated that the carrying value of the MitoCareX reporting unit was in excess of its fair value.
Therefore, the Company recorded during the nine months ended September 30, 2026 a non-cash impairment loss of $
NOTE 5 – INVESTMENT AND LOAN TO SOLTERRA
| 1. | On
June 30, 2024, the Company entered into a 24-month Loan Agreement with Solterra Renewable
Energy Ltd. (“Solterra”) and other lenders, under which the Company committed
€ |
On June 30, 2026, the Company entered into an assignment agreement with Solterra and SE, pursuant to which, subject to the completion of the transaction contemplated by the agreement with Sunflower Sustainable Investments Ltd. (“Sunflower”), the Company agreed to assign to SE all of its rights under the Loan Agreement in consideration for an amount equal to the outstanding loan balance, including accrued interest and linkage differences.
| 19 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 5 – INVESTMENT AND LOAN TO SOLTERRA (continued)
Following the completion of the transaction with Sunflower, the assignment of the Company’s rights under the Loan Agreement became effective. Accordingly, the Company derecognized the original loan receivable and recognized a receivable from SE for the consideration due under the assignment agreement.
On
July 31, 2026, the Company received €
The Company’s chairman of the board of directors also serves as a director of SE.
| 2. | During
2024, the Company acquired |
The
investment is measured at fair value in accordance with ASC 321. The fair value of the investment as of September 30, 2026, was
$
NOTE 6 – SOLAR PHOTOVOLTAIC JOINT VENTURE PROJECT
| 1. | On
July 31, 2024, the Company entered into a Loan and Partnership Agreement with Horizons RES
PE1 UG (haftungsbeschränkt) & Co. KG a German partnership (the “Partnership”),
Solterra, and other lenders, under which the Company committed € |
During
2025, the Company and the other lenders entered into several amendments and additional loan agreements in connection with the Germany
project, pursuant to which the Company committed to provide additional funding, including €
On
June 4, 2026, the parties entered into Addendum No. 3 to the Loan and Partnership Agreement. Subject to the closing of the contemplated
transaction involving Sunflower., the Addendum provides, among other things, for the repayment of
As
of September 30, 2026, the Company has funded €
The Company’s interest in the Partnership was evaluated under ASC 810-10, and the Company determined that the Partnership is not subject to consolidation by the Company. Accordingly, the Partnership is not consolidated in the Company’s consolidated financial statements.
| 20 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 6 – SOLAR PHOTOVOLTAIC JOINT VENTURE PROJECT (continued)
The Company elected to account for the Loan and Partnership Agreement under the fair value option in accordance with ASC 825. The Company estimated the fair value of the Loan and Partnership Agreement using a third-party appraiser and various assumptions such as, probability of completion of the project based on key milestones, scenarios for the expected project’s cash realization value (including expected power of the project, selling price per megawatt, and loan repayment dates). The projected net cash flows were discounted using an interest rate appropriate for similar projects. The result was adjusted to the probability for the completion of the project as of the valuation date.
The
interest rate was determined at
| 2. | On
May 6, 2025, the Company, together with other investors, entered into a loan agreement with
Soltra Renewable Energies Ltd. (the “Borrower”), an Israeli traded company, to
finance the development of a battery storage project in Poland known as the “Pikozow
Project.” Under the agreement, the Company extended a loan in the principal amount
of € |
In
the event the project is sold to a third party not related to the Borrower during a 30 months term,
If
the project is not sold by the end of the term of the loan, the loan will bear annual interest of
The Company assessed its involvement in the Pikozow Project in accordance with ASC 810-10, Variable Interest Entities (VIE), and concluded that the Borrower does not meet the definition of a VIE. Accordingly, no consolidation is required.
On June 4, 2026, the Company assigned its rights under the loan agreement to Solterra, as part of the transaction described above. Upon effectiveness of the assignment, the Company’s rights to participate in future profits from the project were terminated, and the loan receivable was derecognized.
The
Company received €
| 21 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 7 – SHARE EXCHANGE TRANSACTION AND INVESTMENT IN VOICE ASSIST, INC.
On
January 13, 2026, the Company entered into a Securities Exchange Agreement with Voice Assist, Inc. (“Voice Assist”), pursuant
to which the Company agreed to transfer to Voice Assist approximately
In addition, the Company entered into a Services Agreement with Voice Assist pursuant to which the Company will provide advisory and related services. The consideration under the Services Agreement includes deferred cash payments contingent upon future financing transactions of Voice Assist, royalty-based consideration from future projects, and contingent proceeds related to certain claims, as defined in the agreement. The Services Agreement does not have a specified termination date. The Company expects its continuing involvement under the Services Agreement to continue for as long as the advisory and related services are required by Voice Assist and the related contingent consideration arrangements remain in effect; however, the Company cannot reasonably estimate the exact period during which such involvement will continue.
On
March 15, 2026, the Company closed the transaction for the sale of its equity interests in Save Foods Ltd., in which the Company previously
held approximately
The
consideration received by the Company consisted of
The Company evaluated whether it has the ability to exercise significant influence over Voice Assist in accordance with ASC 323. Based on the Company’s ownership percentage and other relevant facts and circumstances, including the absence of board representation, participation in policy-making processes, or other rights to participate in operating or financial decisions of Voice Assist, the Company concluded that it does not have significant influence over Voice Assist.
Accordingly, the investment in Voice Assist is accounted for as an equity security in accordance with ASC 321 and is measured at fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations.
As
of September 30, 2026, the fair value of the Company’s investment in Voice Assist was approximately $
| 22 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 8 – DISCONTINUED OPERATIONS
Disposal of Save Foods Ltd.
During 2025, the Company committed to a plan to sell Save Foods Ltd. (the Company’s pathogen prevention and shelf-life extension segment) and determined that the disposal represented a strategic shift that had a major effect on the Company’s operations and financial results. Accordingly, the operations of Save Foods Ltd. were classified as discontinued operations in accordance with
ASC 205-20.
On
March 15, 2026, the Company closed the transaction for the sale of its equity interests in Save Foods Ltd., in which the Company previously
held approximately
As of September 30, 2026, following the closing of the transaction, the assets and liabilities of Save Foods Ltd. were no longer included in the Company’s consolidated balance sheet.
During
the nine months ended September 30, 2026, the Company recognized a gain from deconsolidation of Save Foods Ltd. of approximately $
Results of operations of Save Foods Ltd. included in discontinued operations were as follows:
SCHEDULE OF DISCONTINUED OPERATIONS
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Nine months ended | Three months ended | |||||||||||||||
| September 30 | September 30 | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues from sales of products | - | |||||||||||||||
| Cost of sales | ( | ) | ( | ) | - | ( | ) | |||||||||
| Gross profit | - | - | ||||||||||||||
| Research and development expenses | - | ( | ) | - | ( | ) | ||||||||||
| Selling and marketing expenses | ( | ) | ( | ) | - | ( | ) | |||||||||
| General and administrative expenses | ( | ) | ( | ) | - | ( | ) | |||||||||
| Operating income (loss) | ( | ) | ( | ) | - | ( | ) | |||||||||
| Finance income (expenses), net | ( | ) | - | |||||||||||||
| Other income | - | - | - | |||||||||||||
| Gain (loss) before gain from deconsolidation | ( | ) | ( | ) | - | ( | ) | |||||||||
| Gain from deconsolidation of subsidiary | - | - | ||||||||||||||
| Net gain (loss) from discontinued operations | ( | ) | ( | ) | ||||||||||||
| Less: net loss from discontinued operations attributable to non-controlling interests | - | |||||||||||||||
| Net income (loss) from discontinued operations attributable to the Company | ( | ) | ( | ) | ||||||||||||
| 23 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 8 –DISCONTINUED OPERATIONS (continued)
Cash flows from discontinued operations for the nine months ended September 30, 2026 and 2025:
| 2026 | 2025 | |||||||
| Nine months ended | ||||||||
| September 30 | ||||||||
| 2026 | 2025 | |||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Net cash used in investing activities | - | |||||||
Supplemental disclosure of Deconsolidation of Save Foods Ltd. as of March 15, 2026:
SCHEDULE OF DECONSOLIDATION ASSETS AND LIABILITIES
| USD in thousands | ||||
| A. Net assets deconsolidated | ||||
| Total assets deconsolidated | ||||
| Total liabilities deconsolidated | ( | ) | ||
| Net assets deconsolidated | ||||
| B. Reconciliation of gain on deconsolidation | ||||
| Noncash consideration — Voice Assist shares | ||||
| Net assets deconsolidated | ( | ) | ||
| Non-controlling interest deficit derecognized | ( | ) | ||
| Gain from deconsolidation of subsidiary | ||||
| C. Net cash flows from deconsolidation | ||||
| Cash consideration received | - | |||
| Cash and cash equivalents deconsolidated | ( | ) | ||
| Net cash used in investing activities upon deconsolidation | ( | ) | ||
| 24 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 9 – CREDIT FACILITY
On
October 1, 2024, the Company entered into a facility agreement with L.I.A. Pure Capital Ltd. (the “Lender”) for financing
of up to €
On
May 27, 2026, the Company and the Lender released from escrow the signatures to an amended and restated facility agreement (the “Amended
Facility Agreement”), which amended and restated the Original Facility Agreement in its entirety. The Amended Facility Agreement
increased the maximum amount available under the Pure Capital Credit Facility from €
The
facility will expire upon full drawdown or
In
connection with the Pure Capital Credit Facility, the Company issued a five-year warrant to the Lender. In accordance with the anti-dilution
provisions of the warrant agreement and following the Company’s entry into the PIPE Agreement, the exercise price of the warrant
was adjusted during 2025. As adjusted to reflect the April Reverse Stock Split and the November Reverse Stock Split, immediately prior to the
execution of the Amended Facility Agreement, the warrant was exercisable for
Under
the Amended Facility Agreement, the terms applicable to the warrant were amended such that the warrant became exercisable for
Prior to September 29, 2026, the Company determined that, due to certain anti-dilution provisions, the warrant was not indexed to the Company’s own stock and, accordingly, was accounted for as a liability measured at fair value at each reporting date. Changes in fair value are recognized in the consolidated statements of operations until reclassification on September 29, 2026.
On September 29, 2026, the Company and the Lender entered into an agreement to amend and restate the warrant, effective on that date. The amended and restated warrant superseded and replaced the previously outstanding warrant and removed certain provisions that had resulted in liability classification. In addition, a provision of the amended facility agreement requiring the Company, following a dilutive issuance resulting in a reduction of the warrant’s exercise price, to issue an additional warrant to the Lender covering a number of shares calculated to preserve the aggregate exercise price payable prior to such issuance was eliminated. The amendment did not increase the number of shares issuable upon exercise of the warrant, extend its term or otherwise provide additional economic consideration to the Lender.
| 25 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 9 – CREDIT FACILITY (continued)
Following
the amendments, the Company reassessed the warrant under ASC 815-40 and concluded that it qualified for equity classification. Immediately
prior to reclassification on September 29, 2026, the Company remeasured the warrant liability to its fair value of $
The Company estimated the fair value of the warrant liability as of September 29, 2026 (immediately prior to its reclassification), and December 31, 2025, using the Black-Scholes option pricing model.
The assumptions used to perform the calculations are detailed below:
SCHEDULE OF ESTIMATED FAIR VALUE OF WARRANT SHARES
| Fair value of warrant liability | September 29, 2026 | December 31, 2025 | ||||||
| Expected volatility (%) (*) | % | % | ||||||
| Risk-free interest rate (%) | % | % | ||||||
| Expected dividend yield | % | % | ||||||
| Expected term of warrants (years) | ||||||||
| Exercise price (US dollars) | $ | $ | ||||||
| Share price (US dollars) | $ | $ | ||||||
| Fair value (U.S. dollars) | $ | $ | ||||||
| (*) |
On
October 7, 2026, subsequent to the balance sheet date, the Lender exercised a portion of the warrants issued, resulting in aggregate
cash proceeds to the Company of approximately $
The Company elected to account for the loans drawn under the Pure Capital Credit Facility under the fair value option in accordance with ASC 825.
As
of September 30, 2026, the Company reassessed the fair value of the outstanding loans based on the contractual repayment provisions and
the financing transactions completed during the period. As a result of these financing transactions, the Lender became entitled to repayment
of the outstanding loan balance. Accordingly, the Company determined that the fair value of the loans approximated the outstanding principal
and accrued interest, amounting to approximately $
| 26 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 10 – COMMON STOCK AND WARRANTS
| 1. | On
January 2, 2025, the Company consummated a Private Placement transaction contemplated by
the securities purchase agreement, dated December 10, 2024, and issued |
The
number of shares, pre-funded warrants and warrants, as well as the exercise prices presented in this note, have been adjusted to reflect
the
The Company considered the guidelines of ASC 815 and determined that the warrants issued in Private Placement meet the definition of a liability and were therefore classified as warrant liabilities in the balance sheet. The pre-funded warrants were classified as equity.
During 2025, certain holders exercised their warrants, and the Company remeasured the related warrant liabilities through the respective exercise dates. During the nine months ended September 30, 2026, there were no exercises of warrants.
The warrant liabilities are measured at fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations.
The fair value of the warrant liabilities was determined using a Black-Scholes option pricing model. The assumptions used to perform the calculations are detailed below:
SCHEDULE OF WARRANT LIABILITIES SHARES ASSUMPTIONS
| Month | Expected volatility (%) (*) | Risk free interest rate | Expected dividend yield | Expected term of options (years) | Exercise price (US dollars) | Share price (US dollars) | Fair value (U.S. dollars) | |||||||||||||||||||||
| September 30, 2026 | % | % | % | $ | $ | $ | ||||||||||||||||||||||
| (*) |
| 2. | On May 12, 2025, the Company, entered into a Purchase Agreement (the “Agreement”) with YA II PN, Ltd. (the “Investor”) as part of the Standby Equity Purchase Agreement dated as of December 22, 2023 (the “SEPA II”). |
On
August 12, 2025, pursuant to the Purchase Agreement, the Company issued a promissory note in the principal amount of $
On
January 22, 2026, the Company issued
| 27 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 10 – COMMON STOCK AND WARRANTS (continued)
| 3. | On
January 8, 2026, the Company issued |
| 4. | On
February 9, 2026, the board of directors of the Company approved the issuance of an equity
grant to executive officers, Company’s chairman of the board and consultant amounting
to a total of |
| 5. | On
February 23, 2026, the Company issued an aggregate of |
| 6. | On
June 12, 2026, the Company entered into a securities purchase agreement with certain investors
pursuant to which the Company issued and sold |
The
First PIPE Warrants had an initial exercise price of $
The Company considered the guidance in ASC 815-40 and determined that, prior to their amendment, the First PIPE Warrants were not indexed to the Company’s own stock. Accordingly, the First PIPE Warrants were classified as liabilities and are remeasured at fair value at each reporting date through September 29, 2026, with changes in fair value recognized in the Condensed Consolidated Statements of Operations.
| 28 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 10 – COMMON STOCK AND WARRANTS (continued)
The fair value of the First PIPE Warrants liabilities at initial recognition, and on September 29, 2026 (immediately prior to its reclassification), was determined using a Black-Scholes option pricing model under probability-weighted scenarios reflecting the anti-dilution provisions then in effect. The assumptions used in the valuations are detailed below:
SCHEDULE OF WARRANTS LIABILITIES
| Fair value of First PIPE Warrants liabilities | September 29, 2026 | June 15, 2026 | ||||||
| Expected volatility (%) (*) | % | % | ||||||
| Risk-free interest rate (%) | % | % | ||||||
| Expected dividend yield | % | % | ||||||
| Expected term of warrants (years) | ||||||||
| Contractual exercise price (US dollars) | $ | $ | ||||||
| Potential adjusted exercise price range (US dollars) | $ | $ | ||||||
| Share price (US dollars) | $ | $ | ||||||
| Fair value (U.S. dollars) | $ | $ | ||||||
| (*) |
The
fair value of the First PIPE Warrants liabilities upon initial recognition on June 15, 2026 was approximately $
On September 29, 2026, the Company entered into amendments to the First PIPE Warrants, which removed certain provisions that previously resulted in liability classification. Following these amendments, the Company determined that the First PIPE Warrants met the requirements for equity classification under ASC 815-40.
Immediately
prior to reclassification, the Company remeasured the First PIPE Warrants liabilities to their fair value of approximately $
The
Company subsequently reclassified the warrant liabilities of $
| 29 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 10 – COMMON STOCK AND WARRANTS (continued)
| 7. | On
June 22, 2026, the Company entered into a securities purchase agreement with certain investors
pursuant to which the Company issued and sold |
The
Second PIPE Warrants had an initial exercise price of $
The Company considered the guidance in ASC 815-40 and determined that, prior to their amendment, the Second PIPE Warrants were not indexed to the Company’s own stock. Accordingly, the Second PIPE Warrants were classified as liabilities and are remeasured at fair value at each reporting date through September 29, 2026, with changes in fair value recognized in the Condensed Consolidated Statements of Operations.
The fair value of the Second PIPE Warrants liabilities at initial recognition, and on September 29, 2026 (immediately prior to its reclassification), was determined using a Black-Scholes option pricing model under probability-weighted scenarios reflecting the anti-dilution provisions of the Second PIPE Warrants. The assumptions used in the valuations are detailed below:
SCHEDULE OF WARRANTS LIABILITIES
| Fair value of Second PIPE Warrants liabilities | September 29, 2026 | June 24, 2026 | ||||||
| Expected volatility (%) (*) | % | % | ||||||
| Risk-free interest rate (%) | % | % | ||||||
| Expected dividend yield | % | % | ||||||
| Expected term of warrants (years) | ||||||||
| Contractual exercise price (US dollars) | $ | $ | ||||||
| Potential adjusted exercise price range (US dollars) | $ | $ | ||||||
| Share price (US dollars) | $ | $ | ||||||
| Fair value (U.S. dollars) | $ | $ | ||||||
| (*) |
The
fair value of the Second PIPE Warrants liabilities upon initial recognition on June 24, 2026 was approximately $
| 30 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 10 – COMMON STOCK AND WARRANTS (continued)
On September 29, 2026, the Company entered into amendments to the Second PIPE Warrants, which removed certain provisions that previously resulted in liability classification. Following these amendments, the Company determined that the Second PIPE Warrants met the requirements for equity classification under ASC 815-40.
Immediately
prior to reclassification, the Company remeasured the Second PIPE Warrants liabilities to their fair value of approximately $
The
Company subsequently reclassified the warrant liabilities of $
| 8. | On
August 31, 2026, the Company issued |
| 9. | During
the nine months ended September 30, 2026, the Company recorded share base compensation expenses
in General and Administrative expenses in the amount of $ |
NOTE 11 – STOCK OPTIONS AND RESTRICTED STOCK UNITS
The following table presents the Company’s stock option activity under its equity incentive plans for the nine months ended September 30, 2026:
SCHEDULE OF STOCK OPTION ACTIVITY
Number of Options | Weighted Average Exercise Price | |||||||
| Outstanding at December 31, 2025 | ||||||||
| Granted | - | - | ||||||
| Exercised | - | - | ||||||
| Forfeited or expired | ( | ) | ||||||
| Outstanding at September 30, 2026 | ||||||||
| Number of options exercisable at September 30, 2026 | ||||||||
During the nine months ended September 30, 2026, following the sale of Save Foods Ltd., a former subsidiary of the Company, certain options previously granted to employees of Save Foods Ltd. were forfeited in accordance with the terms of the applicable awards.
The
aggregate intrinsic value of the awards outstanding as of September 30, 2026, was $
On
October 20, 2025, the Company granted
| 31 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 11 – STOCK OPTIONS AND RESTRICTED STOCK UNITS (continued)
On
September 23, 2026, the Company entered into an RSU Cancellation and Cash Settlement Agreement with Mr. Silberman, pursuant to which
all outstanding RSUs, whether vested or unvested, were cancelled, in consideration for a one-time cash payment of $
In accordance with ASC 718, the Company accelerated the recognition of the remaining unrecognized compensation cost. As the cash consideration did not exceed the fair value of the RSUs at the settlement date, the payment was recorded as a reduction of additional paid-in capital, and no incremental compensation expense was recognized in connection with the cash settlement.
Costs
incurred in respect of stock-options and RSUs compensation for employees and directors for the nine and three months ended September
30, 2026 were $
NOTE 12 – RELATED PARTIES
| A. | Transactions and balances with related parties |
SCHEDULE OF TRANSACTIONS AND BALANCES WITH RELATED PARTIES
| 2026 | 2025 | |||||||
| Nine months ended September 30 | ||||||||
| 2026 | 2025 | |||||||
| General and administrative expenses: | ||||||||
| Directors’ compensation | ||||||||
| Salaries and fees to officers | ||||||||
| Total General and administrative expenses | (*) | (*) | ||||||
| (*) of which share based compensation | ||||||||
| Research and development expenses: | ||||||||
| Salaries and fees to officers | - | |||||||
| (*) | - | |||||||
| (*) Includes share-based compensation | - | |||||||
| (*) |
| B. | Balances with related parties and officers: |
| As of September 30, | As of December 31, | |||||||
| 2026 | 2025 | |||||||
| Other accounts payables | ||||||||
| 32 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 13 – SEGMENT REPORTING
| A. | Information about reported segment of profit or loss and assets |
As of September 30, 2026, the Company has two reportable segments: (i) Biotechnology activity, and (ii) Renewable energy projects. The Biotechnology operating segment consists of MitoCareX from the acquisition date, and the Renewable energy projects operating segment consists of NITO Renewable Energy, Inc. and Solar photovoltaic joint venture project.
The CODM evaluates performance and allocates resources based primarily on segment operating loss. Prior period segment information has been recast to conform to the current year presentation.
The following table presents information about the Company’s reportable segments for the nine and three months ended September 30, 2026, and 2025:
SCHEDULE OF INFORMATION RELATED TO OPERATIONS OF REPORTABLE OPERATING SEGMENTS
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Nine months ended | Three months ended | |||||||||||||||
| September 30 | September 30 | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue from biotechnology activity | - | - | - | - | ||||||||||||
| Cost related to biotechnology activity (*) | ( | ) | - | ( | ) | - | ||||||||||
| Salaries and related expenses related to biotechnology activity | ( | ) | - | ( | ) | - | ||||||||||
| Amortization of intangible asset | ( | ) | - | ( | ) | - | ||||||||||
| Operating loss from Biotechnology activity | ( | ) | - | ( | ) | - | ||||||||||
| Revenue from renewable energy projects | - | - | - | - | ||||||||||||
| Cost related to renewable energy projects | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Operating loss from renewable energy projects | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Professional services | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Share base compensation | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Change in fair value of contingent consideration | - | - | ||||||||||||||
| Goodwill impairment | ( | ) | - | - | - | |||||||||||
| Depreciation | ( | ) | - | ( | ) | - | ||||||||||
| Other general and administrative expenses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest of loans | ( | ) | ( | ) | ( | ) | - | |||||||||
| Financing expenses, net | ( | ) | ( | ) | ||||||||||||
| Other income | - | |||||||||||||||
| Changes in fair value of investments measured under the fair value option | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net gain (loss) before tax | ( | ) | ( | ) | ||||||||||||
| Income taxes | - | - | ||||||||||||||
| Net gain (loss) | ( | ) | ( | ) | ||||||||||||
| (*) |
| 33 |
NEXENTIS TECHNOLOGIES INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)
(USD in thousands, except share and per share data)
NOTE 14 – SUBSEQUENT EVENTS
| 1. | On
October 7, 2026, the Lender exercised warrants issued in connection with the Pure Capital Credit Facility for an aggregate cash
consideration of approximately $ |
| 2. | On
October 15, 2026, the Company issued |
| 3. | On
October 26, 2026, the Company issued | |
| 4. | On
November 9, 2026, the Company effected a | |
| All share, stock option, warrants and per share information presented in these consolidated financial statements has been retroactively adjusted to reflect the reverse stock split for all periods presented. See also Note 1B. |
| 5. | On November 9, 2026, the Company issued an aggregate of |
| 34 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and related notes included elsewhere in this Quarterly Report. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. See “Forward-Looking Statements” for a discussion of the uncertainties and assumptions associated with these statements. Our actual results may differ materially from those discussed below.
All information in this Quarterly Report relating to shares or price per share reflects the 1-for-35 reverse stock split effected by us on September 22, 2025 and the 1-for-7 reverse stock split effected by us on April 8, 2026 and the 1-for-5 reverse stock split effected by us on November 9, 2026.
Overview
We are focused on sustainable operations in various industries such as oncology biotechnology and solar projects. Our activities are advancing innovative oncology solutions through MitoCareX to improve cancer treatment outcomes.
We currently operate through our wholly owned Israeli subsidiary and our Nevada wholly-owned subsidiary and collaborate and invest in a joint venture in the solar energy sector:
MitoCareX, which has been our wholly owned subsidiary since October 2025, develops and advances targeted therapeutics for diverse types of indications by focusing on transport proteins (i.e., transporters). MitoCareX develops technologies that are designed to interact with transporters, thereby potentially disrupting the disease. MitoCareX routinely utilizes structural biology in combination with computational chemistry to discover, design and develop drug candidates that interact with its protein targets of interest. MitoCareX’s approach leverages a proprietary MITOLINE™ algorithm, which enables the reliable generation of 3D molecular structural models of MitoCareX’s protein targets and allows for large-scale virtual screening campaigns against these targets. MITOLINE™ provides a platform-level starting point to enable modelling and further allows to discover potential therapeutics. A key advantage of MitoCareX platform is its ability to address the historical lack of experimental structural data that has limited drug discovery efforts targeting MitoCareX’s proteins of interest, thereby potentially expanding the druggable target space. By enabling rational, structure-guided discovery at scale, MitoCareX’s solutions are designed to unlock new treatment opportunities. Recently, MitoCareX entered into an engagement with Boltz, PBC (“Boltz”), an AI research lab that focuses on biomolecular foundation models and drug discovery workflows, to accelerate the identification of potential therapeutics targeting selected proteins of interest to MitoCareX’s pipeline. In October 2026, MitoCareX completed an initial computational screening stage under this initiative.
We collaborate with Solterra Renewable Energy Ltd., an Israeli corporation (“Solterra”) and a former wholly-owned subsidiary of Solterra Energy Ltd., an Israeli public corporation, listed on the Tel Aviv Stock Exchange (“Solterra Energy”), which operates in the solar energy sector and presents certain investment opportunities in solar photovoltaic (“PV”) projects. Solterra engages in the development of renewable energy projects through its subsidiaries. Currently, operations are conducted in Italy, Poland, and Germany, with potential expansion to additional countries. Our subsidiary, NITO Renewable, was established in February 2025 in the State of Nevada and has a 70% interest in the joint venture in Italy. Solterra’s business strategy primarily involves selling renewable energy projects to third parties at various stages of development, from the initial land identification and project advancement through construction, operation, or sale to a third party. Currently, most projects are expected to be sold at various development stages, with the possibility of a larger portion of projects being held long-term for operation by Solterra in the future. In July 2026, Solterra Energy completed the sale of 100% of the issued share capital of Solterra to Sunflower Sustainable Investments Ltd., an Israeli public corporation listed on the Tel Aviv Stock Exchange. We currently intend to continue to collaborate with Solterra as Solterra surveys the European solar energy market for additional projects.
| 35 |
During 2025, the Company underwent significant changes to its business operations. In April 2025, the Company completed the sale of its NTWO OFF Ltd. operations. In addition, during 2025, the Company classified the operations of Save Foods Ltd., our former 98.48% owned subsidiary (“Save Foods”), as held for sale and discontinued operations. Accordingly, the results of these operations are presented separately in the consolidated financial statements and are not included in the discussion of continuing operations below.
As a result of these changes, the Company’s consolidated financial statements for the periods presented have been reclassified to conform to the current presentation, and therefore may not be directly comparable to prior periods. Unless otherwise indicated, the discussion below relates to the Company’s continuing operations.
On January 13, 2026, we entered into a Securities Exchange Agreement (the “SF Agreement”) with Voice Assist, Inc., a public company incorporated under the laws of the State of Nevada (“Voice Assist”), and, for certain limited purposes set forth therein, Save Foods. On January 13, 2026, we also entered into a Services Agreement with Voice Assist (the “Services Agreement”), pursuant to which we will provide non-exclusive general advisory, support, collaboration and related services to Voice Assist from time to time for consideration consisting of deferred cash from future Voice Assist financings (subject to a $1,000,000 cap), royalty consideration on “New Future Projects” (as defined in the Services Agreement) over specified periods, and a share of any “Ecolab Gross Proceeds” (as defined in the Services Agreement) related to the Ecolab Claim, and the Services Agreement includes successor obligations with respect to royalty consideration and a term through calendar year 2026 with the Company’s extension rights until consideration is fully received. On March 15, 2026, we closed the SF Agreement (the “Closing”). At the Closing, we transferred to Voice Assist all of the ordinary shares of Save Foods owned by us, representing approximately 98% of the issued and outstanding ordinary share capital of Save Foods, free and clear of any encumbrances and Voice Assist delivered to us number of shares of common stock of Voice Assist, par value $0.001 per share, that represented 19.99% of Voice Assist shares of common stock.
We currently own 19.99% of Voice Assist.
Additionally, we currently own approximately 8.2% of Plantify Foods Inc. (“Plantify”), a Canadian-based public company listed on the TSX Venture Exchange that was previously engaged in the food tech industry primarily through its Israeli subsidiary, Piece of Bean Ltd. (“Piece of Bean”), which was involved in the production and distribution of clean label food. Piece of Bean’s factory and business operations, located in Kibbutz Gonen in the Golan Heights, were severely impacted by the recent war in Israel, and Piece of Bean is in the process of voluntary insolvency proceedings. As a consequence, Plantify currently has essentially no business activity and minimal liquidity.
Recent Developments
Nasdaq Listing Compliance
On August 31, 2026, we received a letter (the “Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that our stockholders’ equity of $1,782,000, as reported in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, was below the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2,500,000. The Letter had no immediate impact on the listing or trading of our common stock on The Nasdaq Capital Market. Pursuant to the Letter, we had 45 calendar days, or until October 15, 2026, to submit a plan to regain compliance and, if such plan is accepted, the Listing Qualifications Staff may grant an extension of up to 180 calendar days from the date of the Letter, or through February 27, 2027, to evidence compliance. On October 10, 2026, we submitted a plan to regain compliance to the Listing Qualifications Staff.
| 36 |
On September 29, 2026, we entered into amendment agreements (the “Amendment Agreements”) with the holders of all outstanding warrants issued in connection with (i) our credit facility with L.I.A. Pure Capital Ltd., originally entered into on October 1, 2024 and amended and restated in May 2026, (ii) our concurrent private placement conducted alongside our registered direct offering that closed on June 15, 2026 and (iii) our concurrent private placement conducted alongside our registered direct offering that closed on June 24, 2026 (collectively, the “Existing Warrants”). Pursuant to the Amendment Agreements, the parties agreed to amend the Existing Warrants and enter into amended and restated warrants (the “Amended Warrants” and, together with the Amendment Agreements, the “Amendments”). The Amended Warrants removed certain provisions contained in the Existing Warrants that resulted in liability classification for accounting purposes, and we determined that the Amended Warrants qualify for equity classification under applicable accounting guidance. The Amendments did not increase the number of shares issuable upon exercise of the Existing Warrants, extend their terms or otherwise provide additional economic consideration to the holders thereof, and were effected in connection with our efforts to regain compliance with Nasdaq Listing Rule 5550(b)(1). As a result of the Amendments and the non-cash financing income recognized during the third quarter of 2026, our reported stockholders’ equity as of September 30, 2026 was $12,774,000, which exceeded the minimum requirement of $2,500,000. However, Nasdaq will continue to monitor our compliance with the stockholders’ equity requirement, and there can be no assurance that Nasdaq will determine that we have regained compliance, that we will be able to maintain compliance with Nasdaq Listing Rule 5550(b)(1) or any other continued listing requirement, or that our common stock will not be delisted.
Subsequent Equity Issuances and Warrant Exercises
On October 7, 2026, we issued 110,337 shares of common stock upon the exercise of outstanding warrants.
On October 15, 2026, we issued an aggregate of 184,438 shares of common stock to our directors, executive officers and consultants in consideration of services provided to the Company. Of these shares, 82,438 were issued pursuant to the Company’s 2022 Share Incentive Plan to our Chief Executive Officer, our Chief Financial Officer, our directors and a consultant, while the remaining 102,000 shares were issued to consultants outside the plan for financial, investor relations and business development services.
On October 26, 2026, we issued an additional 2,000 shares of common stock to a consultant in consideration of services provided to the Company.
2026 Annual Meeting and Proposed Convertible Note Financing Facility
On November 9, 2026, we filed a preliminary proxy statement with the SEC for our 2026 annual meeting of stockholders, scheduled to be held on December 30, 2026, at which our stockholders will be asked, among other things, to approve, for purposes of Nasdaq Listing Rule 5635(d), (i) the issuance of up to 20,000,000 shares of common stock (subject to adjustment for any reverse stock split effected prior to such offerings), for aggregate consideration of up to $100 million, in one or more non-public offerings at a maximum discount of 20% below the market price of our common stock, and (ii) the potential issuance of shares of common stock pursuant to a proposed convertible note financing facility with a single investor, under which we may issue unsecured convertible promissory notes in an aggregate principal amount of up to $10 million, together with warrants and shares issuable as a commitment fee.
We have negotiated with a single investor (the “Investor”) the material terms of a proposed convertible note financing facility. We and the Investor have not yet entered into definitive agreements with respect to the proposed financing. We presently intend to enter into definitive agreements with the Investor following receipt of the stockholder approval sought pursuant to this Proposal, substantially on the terms described below. The proposed definitive agreements are expected to consist of a Securities Purchase Agreement (the “Purchase Agreement”), unsecured convertible promissory notes to be issued thereunder (the “Notes”) and warrants to purchase shares of our common stock to be issued in connection with each Note (the “Warrants,” and together with the Purchase Agreement and the Notes, the “Transaction Documents”). The shares of common stock issuable upon conversion of the Notes are referred to as the “Conversion Shares,” the shares of common stock issuable upon exercise of the Warrants are referred to as the “Warrant Shares,” and the shares of common stock proposed to be issued as a commitment fee are referred to as the “Commitment Shares.”
| 37 |
Under the proposed Purchase Agreement, we would be permitted to issue and sell to the Investor, from time to time, Notes in an aggregate principal amount of up to $10 million. Upon execution of the Purchase Agreement (the “Initial Closing”), the Investor would purchase from us a Note in the principal amount of $1,500,000 for a purchase price of $1,350,000. Commencing on January 1, 2027, we would be permitted to request, in our sole discretion, that the Investor purchase additional Notes, with the aggregate principal amount of Notes issued during each calendar quarter not to exceed $1,500,000. Each Note would be issued at a purchase price equal to 90% of its principal amount, reflecting a 10% original issue discount.
Each Note would mature 28 months after its issuance date and would bear interest at an annual rate of 8%, which would increase to 14% upon an event of default for so long as the event remains uncured. The principal amount of each Note, together with accrued and unpaid interest, would be payable in 10 equal monthly installments beginning on the first day of each month following the 18-month anniversary of the applicable issuance date, unless repaid earlier in accordance with the Note or the maturity date is extended at the option of the Investor.
The outstanding amounts due under each Note would be convertible into shares of our common stock at the option of the Investor at any time after the issuance date of the Note at a conversion price per share equal to the lower of (i) the closing price of our common stock on the trading day immediately preceding the date on which our stockholders approve this Proposal (the “Fixed Price”), and (ii) 88% of the lowest daily volume-weighted average price of our common stock during the 20 consecutive trading days immediately preceding the applicable conversion date, provided that the variable conversion price per share may not be lower than 20% of the Fixed Price (the “Floor Price”), subject to certain adjustments as provided in the Note. The Investor’s right to convert a Note would be subject to the limitation that a conversion may not result in the Investor and its affiliates beneficially owning more than 4.99% of our outstanding common stock.
At each closing under the Purchase Agreement, we would also issue to the Investor a Warrant to purchase a number of shares of common stock equal to 100% of the Conversion Shares underlying the Note issued at that closing, determined by dividing the principal amount of the applicable Note by the variable conversion price then in effect. Each Warrant would have an exercise price per share equal to 80% of the Fixed Price and would expire 60 months after issuance, in each case subject to adjustment as provided in the Warrant. The Investor’s right to exercise a Warrant would also be subject to a 4.99% beneficial ownership limitation.
In consideration for the Investor’s execution and delivery of the Purchase Agreement, at the Initial Closing we would issue to the Investor a number of Commitment Shares equal to 4.99% of the number of shares of our common stock outstanding immediately after giving effect to such issuance.
Under the proposed Purchase Agreement, we would be required to prepare and file with the Securities and Exchange Commission, as soon as practicable but no later than 30 trading days after execution of the Purchase Agreement, a resale registration statement covering the Conversion Shares, the Warrant Shares and the Commitment Shares, and to use reasonable best efforts to cause the registration statement to become effective within the period specified in the Purchase Agreement.
If a Nasdaq rule establishing a minimum Market Value of Listed Securities requirement of at least $5.0 million for companies listed on the Nasdaq Capital Market becomes effective while any portion of a Note remains outstanding, from and after the effectiveness of such rule, the conversion price under the Notes would be equal to the lower of (i) the Fixed Price and (ii) 50% of the lowest daily volume-weighted average price of our common stock during the 20 consecutive trading days immediately preceding the applicable conversion date, subject to the Floor Price.
Because definitive agreements have not yet been executed, there can be no assurance that the proposed financing will be consummated. If definitive agreements are executed, we expect that the material terms of the financing will be substantially as described in this Proposal. If definitive agreements are executed, the foregoing descriptions will be qualified in their entirety by reference to the full text of the Transaction Documents, which we expect to file with the SEC as required by applicable law.
In addition to the proposals described above, at the 2026 annual meeting, our stockholders will also be asked, among other things, to approve an amendment to our 2022 Share Incentive Plan to increase the number of shares of common stock available for issuance thereunder by an additional 1,000,000 shares of common stock.
| 38 |
Results of Operations
The 2025 comparative amounts presented below have been recast to reflect the classification of the Company’s Save Foods and NTWO OFF Ltd. operations as discontinued operations. Accordingly, the results of these discontinued operations are excluded from continuing operations. Unless otherwise indicated, the discussion below relates only to the Company’s continuing operations.
Operating Expenses
Our current operating expenses consist of five components - research and development expenses, general and administrative expenses, change in fair value of contingent consideration, goodwill impairment and depreciation and amortization.
Research and Development Expenses
Our research and development expenses consist primarily of salaries and related expenses and other related research and development expenses such as field tests.
Nine Months Ended September 30, | Three Months Ended September 30, | |||||||||||||||
| U.S. dollars | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Salaries and related expenses | 599,000 | - | 174,000 | - | ||||||||||||
| Subcontractors | 67,000 | - | 20,000 | - | ||||||||||||
| Laboratory and Field tests | 178,000 | - | 61,000 | - | ||||||||||||
| Other expenses | 92,000 | - | 33,000 | - | ||||||||||||
| Total | 936,000 | - | 288,000 | - | ||||||||||||
General and Administrative Expenses
General and administrative expenses consist primarily of professional services, share based compensation and other non-personnel related expenses.
Nine Months Ended September 30, | Three Months Ended September 30, | |||||||||||||||
| U.S. dollars | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Professional services | 1,763,000 | 1,645,000 | 429,000 | 777,000 | ||||||||||||
| Share based compensation | 1,828,000 | 2,141,000 | 429,000 | 112,000 | ||||||||||||
| Salaries and related expenses | 115,000 | - | 19,000 | - | ||||||||||||
| Legal expenses | 231,000 | 233,000 | 36,000 | 130,000 | ||||||||||||
| Insurance | 94,000 | 106,000 | 32,000 | 32,000 | ||||||||||||
| Registration fees | 54,000 | 61,000 | 15,000 | 18,000 | ||||||||||||
| Other expenses | 56,000 | 15,000 | 25,000 | 2,000 | ||||||||||||
| Total | 4,141,000 | 4,201,000 | 985,000 | 1,071,000 | ||||||||||||
Three months ended September 30, 2026 compared to three months ended September 30, 2025
Research and Development Expenses
Research and development expenses consist of salaries and related expenses, service providers’ costs, related materials and overhead expenses. Research and development expenses for the three months ended September 30, 2026 were $288,000, compared to no research and development expenses for the three months ended September 30, 2025. The increase was attributable to research and development activities following the acquisition of MitoCareX in October 2025, including personnel-related expenses and costs associated with its ongoing development programs.
| 39 |
General and Administrative Expenses
General and administrative expenses consisted primarily of professional services, salaries and related expenses including share based compensation and other non-personnel related expenses, including legal expenses and directors and officers insurance costs. General and administrative expenses for the three months ended September 30, 2026 were $985,000, a decrease of $86,000, or 8%, compared to general and administrative expenses of $1,071,000 for the three months ended September 30, 2025. The decrease was primarily attributable to decrease of professional services and legal expenses, partially offset by an increase of share-based compensation to our employees and service providers.
Change in fair value of contingent consideration
Change in fair value of contingent consideration for the three months ended September 30, 2026 resulted in a non-cash gain of $146,000. The contingent equity consideration was recognized in connection with the acquisition of MitoCareX in October 2025 and is remeasured at fair value at each reporting date, with changes in fair value recognized in the statement of operations. The gain was primarily attributable to a decrease in the market price of the Company’s common stock during the period, which reduced the fair value of the liability associated with the contingent equity consideration.
Depreciation and amortization
Depreciation and amortization for the three months ended September 30, 2026 was $107,000, compared to no depreciation and amortization for the three months ended September 30, 2025. The increase was attributable to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX in October 2025 as part of the purchase price allocation.
Financing income, Net
Financing income, net for the three months ended September 30, 2026 was $7,067,000, an increase of $6,893,000 or 3,961%, compared to financing income, net of $174,000 for the three months ended September 30, 2025. The increase was primarily attributable to non-cash gains resulting from decreases in the fair value of the warrant liabilities associated with our credit facility with L.I.A. Pure Capital Ltd. and the warrants issued in the concurrent private placements that closed in June 2026, primarily due to a decrease in the market price of our common stock during the period. On September 29, 2026, we amended these warrants and, following their final remeasurement to fair value, the warrants were reclassified from liabilities to equity.
Income taxes
Income tax benefit for the three months ended September 30, 2026 was $24,000. The tax benefit is primarily attributable to a reduction in deferred tax liabilities, and does not reflect taxable income generated from operations. The decrease in deferred tax liabilities was primarily related to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX, which resulted in a corresponding income tax benefit.
Net gain from continuing operations
Net gain from continuing operations for the three months ended September 30, 2026, was $5,002,000, compared to $616,000 for the three months ended September 30, 2025, an increase of $4,386,000, or 712%. The increase was primarily attributable to higher financing income, net, as discussed above.
Net gain (loss) from discontinued operations
Net gain from discontinued operations for the three months ended September 30, 2026, was $17,000, compared to a net loss of $246,000 for the three months ended September 30, 2025. The gain in 2026 resulted from a post-closing adjustment related to the reconciliation of outstanding balances following the sale of Save Foods Ltd. in March 2026. The loss in 2025 reflected the operating results of the former Save Foods business.
Total net gain
As a result of the foregoing, our total net gain for the three months ended September 30, 2026 was $5,019,000 compared to $370,000 for the three months ended September 30, 2025, an increase of $4,649,000, or 1,256%.
| 40 |
Nine months ended September 30, 2026 compared to nine months ended September 30, 2025
Research and Development Expenses
Research and development expenses consist of salaries and related expenses, service providers’ costs, related materials and overhead expenses. Research and development expenses for the nine months ended September 30, 2026 were $936,000, compared to no research and development expenses for the nine months ended September 30, 2025. The increase was attributable to research and development activities following the acquisition of MitoCareX in October 2025, including personnel-related expenses and costs associated with its ongoing development programs.
General and Administrative Expenses
General and administrative expenses consisted primarily of professional services, salaries and related expenses including share-based compensation and other non-personnel related expenses, including legal expenses and directors and officers insurance costs. General and administrative expenses for the nine months ended September 30, 2026 were $4,141,000, a decrease of $60,000, or 1%, compared to general and administrative expenses of $4,201,000 for the nine months ended September 30, 2025. The decrease was primarily attributable to decrease of share-based compensation to our employees and service providers and insurance costs , partially offset by an increase of professional services and salaries and related expenses.
Change in fair value of contingent consideration
Change in fair value of contingent consideration for the nine months ended September 30, 2026 was a gain of $349,000. The gain is related to the contingent cash and equity consideration recognized in connection with the acquisition of MitoCareX in October 2025. Following the Company’s financing activities, the contingent cash consideration became fixed and payable and, following its final fair value remeasurement, was reclassified to accrued expenses. The gain reflects the combined effect of changes in the fair value of the contingent cash and equity consideration during the period, including a decrease in the fair value of the contingent equity consideration resulting from a decline in the market price of the Company’s common stock. The remaining contingent equity consideration remains contingent and continues to be measured at fair value at each reporting date.
Goodwill impairment
Goodwill impairment expenses consisted of a non-cash impairment loss of $6.3 million recognized in connection with the goodwill related to the MitoCareX reporting unit during the nine months ended September 30, 2026. The impairment loss was recognized following the Company’s interim goodwill impairment assessment performed during the first quarter of 2026, which was triggered by impairment indicators, including a sustained decline in the Company’s share price and market capitalization. Based on the assessment, the carrying amount of the MitoCareX reporting unit exceeded its estimated fair value. The impairment charge did not impact the Company’s cash flows or liquidity.
Depreciation and amortization
Depreciation and amortization for the nine months ended September 30, 2026 was $316,000, compared to no depreciation and amortization for the nine months ended September 30, 2025. The increase was attributable to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX in October 2025 as part of the purchase price allocation.
Financing expenses, Net
Financing expenses, net for the nine months ended September 30, 2026 was $1,870,000, an increase of $15,000 or 1%, compared to financing expenses, net of $1,855,000 for the nine months ended September 30, 2025. Financing expenses, net for the 2026 period reflect non-cash losses recognized during the first half of 2026 from changes in the fair value of the warrant liabilities associated with the amendment and restatement of our credit facility with L.I.A. Pure Capital Ltd. and the day-one losses recognized upon the issuance of the warrants in the June 2026 private placements, as well as higher interest expenses on outstanding loans and unfavorable foreign currency exchange differences, substantially offset by non-cash gains resulting from decreases in the fair value of such warrant liabilities during the third quarter of 2026. On September 29, 2026, we amended these warrants and, following their final remeasurement to fair value, the warrants were reclassified from liabilities to equity.
| 41 |
Income taxes
Income tax benefit for the nine months ended September 30, 2026 was $70,000. The tax benefit is primarily attributable to a reduction in deferred tax liabilities, and does not reflect taxable income generated from operations. The decrease in deferred tax liabilities was primarily related to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX, which resulted in a corresponding income tax benefit.
Net Loss from continuing operations
Net loss from continuing operations for the nine months ended September 30, 2026, was $13,581,000, compared to $4,887,000 for the nine months ended September 30, 2025, an increase of $8,694,000, or 178%. The increase in net loss from continued operations was primarily attributable to the recognition of a non-cash goodwill impairment loss, as discussed above.
Net gain (loss) from discontinued operations
Net gain from discontinued operations for the nine months ended September 30, 2026 was $851,000, compared to net loss from discontinued operations $508,000 for the nine months ended September 30, 2025 an increase of $1,359,000, or 268%. The increase was primarily attributable to the sale of the Company’s former Save Foods business through a share exchange transaction, which resulted in the elimination of the Company’s negative investment balance in such business. The net loss in the 2025 period related to the operating results of the former Save Foods business, which was classified as discontinued operations during 2025.
Total net loss
As a result of the foregoing, our total net loss for the nine months ended September 30, 2026 was $12,730,000 compared to $5,395,000 for the nine months ended September 30, 2025, an increase of $7,335,000, or 136%.
Liquidity and Capital Resources
Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures. Since our inception through September 30, 2026, we have funded our operations, principally with the issuance of equity and debt.
As of September 30, 2026, we had cash and cash equivalents of $2,837,000, as compared to $6,044,000 as of September 30, 2025. As of September 30, 2026, we had a working capital of $5,679,000, as compared to $6,598,000 as of September 30, 2025. The decrease in our cash balance is mainly attributable to cash provided by financing activities offset by cash used in operations and cash used in investing activities.
On July 23, 2023, we entered into a standby equity purchase agreement with YA II PN, Ltd. (the “Investor”), pursuant to which the Investor agreed to purchase up to $3,500,000 of shares of our common stock for 40 months from the date of the purchase agreement at a price per share equal to 94% of the lowest volume-weighted average price (“VWAP”) of the common stock for the three days prior to the delivery of each advance notice from us, subject to certain limitations, including that the Investor cannot purchase a number of shares that would result in it beneficially owning more than 4.99% of our outstanding shares of common stock. In December 2023, we completed an investment round in the aggregate amount of $3,500,000.
On December 22, 2023, we entered into an additional standby equity purchase agreement with the Investor, pursuant to which the Investor has agreed to purchase up to $20 million of shares of our common stock for 36 months from the date of the purchase agreement at a price per share equal to 94% of the lowest VWAP of our common stock for the three trading days immediately following the delivery of each advance notice from us. The agreement will terminate automatically on the earlier of January 1, 2027, or when the Investor has purchased an aggregate of $20 million of our shares of common stock. We have the right to terminate the purchase agreement upon five trading days’ prior written notice to the Investor. We have sold 5,457 shares of common stock at an average purchase price of $602.45 to the Investor.
| 42 |
In connection with and subject to the satisfaction of certain conditions set forth in the purchase agreement, upon our request, the Investor pre-advanced to us up to $3,000,000 of the $20,000,000 commitment amount (a “Pre-Advance”), with each Pre-Advance to be evidenced by a promissory note (each, a “Note”). The Pre-Advance made to us will be subject to a 3% discount to the principal amount equal to each Note. Each Note accrues interest on the outstanding principal balance at the rate of 8% per annum. The Company is required to pay, on a monthly basis, one tenth of the outstanding principal amount of each Note, together with accrued and unpaid interest, either (i) in cash or (ii) by submitting an Advance notice pursuant to the purchase agreement and selling the Investor shares, or any combination of (i) or (ii) as determined by us. The initial repayment is due 60 days after the issuance of a Note, followed by subsequent payments due every 30 days after the previous payment. Unless otherwise agreed to by the Investor, any funds received by us pursuant to the purchase agreement for the sale of shares will first be used to satisfy any payments due under an outstanding note.
On May 12, 2025, we entered into an amendment to the standby equity purchase agreement with the Investor (the “Purchase Agreement Amendment”) with respect to the balance of approximately $16 million then remaining available under the standby equity purchase agreement, pursuant to which the Investor committed to advance us an aggregate principal amount of $3,000,000.
On August 12, 2025, pursuant to the Purchase Agreement Amendment, we issued a revised promissory note in the principal amount of $1,500,000 to the Investor.
As of November 16, 2026, we have sold 56,431 shares of common stock at an average purchase price of $131.85 to the Investor.
On October 20, 2025, upon fulfillment of all remaining closing conditions set forth in the Securities Purchase and Exchange Agreement, dated February 25, 2025, as amended on May 18, 2025 and July 23, 2025, by and among the Company, MitoCareX, SciSparc Ltd., Dr. Alon Silberman and Prof. Ciro Leonardo Pierri, and as consideration thereunder, the Company remitted a cash payment in the amount of $700,000 to SciSparc Ltd.
On December 10, 2024, we entered into a securities purchase agreement with certain investors for gross proceeds of approximately $1,500,000 in a private placement. The private placement closed on January 2, 2025, at which time we issued 1,392 shares of common stock, pre-funded warrants to purchase 3,711 shares of common stock and warrants to purchase 7,654 shares of common stock.
On October 1, 2024, we entered into a facility agreement with L.I.A. Pure Capital Ltd. On May 27, 2026, following stockholder approval, we and with L.I.A. Pure Capital Ltd. released from escrow the signatures to an amended and restated facility agreement, which increased the total amount available under the credit facility from EUR 6.0 million to EUR 10.0 million. The principal economic terms of the credit facility otherwise remained substantially unchanged. On October 7, 2026, L.I.A. Pure Capital Ltd. exercised warrants issued in connection with the amended and restated facility agreement for an aggregate cash consideration of approximately $552 thousand. The exercise related to 110,337 shares of Common Stock at an exercise price of $5.00 per share. Following the exercise, the warrant remains exercisable for 259,663 shares of Common Stock. See Note 9 for additional information.
On June 12, 2026, we entered into a securities purchase agreement with certain investors for the issuance of 62,379 shares of common stock in a registered direct offering and warrants to purchase 62,379 shares of common stock in a concurrent private placement. The warrants have an exercise price of $20.04 per share. The offerings closed on June 15, 2026, and generated aggregate gross proceeds of approximately $1.25 million, before offering expenses.
On June 22, 2026, we entered into a securities purchase agreement with certain investors for the issuance of 82,204 shares of common stock in a registered direct offering and warrants to purchase 82,204 shares of common stock in a concurrent private placement. The warrants have an exercise price of $35.28 per share. The offerings closed on June 24, 2026, and generated aggregate gross proceeds of approximately $2.9 million, before offering expenses.
| 43 |
The table below presents our cash flows for the periods indicated:
Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net cash used in operating activities | (3,186,000 | ) | (2,311,000 | ) | ||||
| Net cash used in investing activities | (3,351,000 | ) | (1,898,000 | ) | ||||
| Net cash provided by financing activities | 5,376,000 | 8,097,000 | ||||||
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 24,000 | (27,000 | ) | |||||
| Increase (decrease) in cash and cash equivalents | (1,137,000 | ) | 3,861,000 | |||||
Going Concern
Since our incorporation, we incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. As of September 30, 2026, we had an accumulated deficit of $51,253,000, and we expect to incur losses for the foreseeable future. We have financed our operations mainly through fundraising from various investors and have limited revenue from our products and therefore are dependent upon external sources to finance our operations. There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations. These factors raise substantial doubt about our ability to continue as a going concern through at least twelve months from the date of this Quarterly Report.
We believe that our existing capital resources will not be sufficient to support our operating plan during the twelve months following the date of issuance of these financial statements. We will likely seek to raise additional capital to support our growth or other strategic initiatives through the issuance of debt, equity, or a combination thereof. There can be no assurance we will be successful in raising additional capital on favorable terms, or at all.
As a result, there is substantial doubt about our ability to continue as a going concern. If we are unable to obtain sufficient amounts of additional capital, we may be required to reduce the scope of our planned development, which could harm our business, financial condition and operating results. If we obtain additional funds by selling any of our equity, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or the equity securities may have rights preferences or privileges senior to the common stock. If we issue debt securities, there may be negative covenants which may restrict our company’s activities. If adequate funds are not available to our company when needed on satisfactory terms, we may be required to cease operating or otherwise modify our business strategy. The financial statements included in this Quarterly Report do not include adjustments for measurement or presentation of assets and liabilities, which may be required should we fail to operate as a going concern.
Operating Activities
Net cash used in operating activities was $3,186,000 for the nine months ended September 30, 2026, as compared to $2,311,000 for the nine months ended September 30, 2025. The increase is mainly attributable to higher cash used to fund operating activities in the nine months ended September 30, 2026, including MitoCareX’s research and development activities. The increase was partially offset by decrease in prepaid expenses and other current assets, while a decrease in other liabilities increased cash used in operating activities.
| 44 |
Investing Activities
Net cash used in investing activities was $3,351,000 for the nine months ended September 30, 2026, as compared to net cash used in investing activities of $1,898,000 for the nine months ended September 30, 2025. The increase of $1,453,000 was primarily attributable to the investment of $3,300,000 in short-term bank deposits during the 2026 period, compared to no such investments in the corresponding 2025 period. This increase was partially offset by proceeds of $604,000 from repayments of loans related to solar photovoltaic projects, lower investments in solar projects under development and in the solar photovoltaic joint venture project, and the absence of short-term loans granted during the 2026 period, compared to $786,000 of short-term loans granted in the corresponding 2025 period. These offsetting factors were partially reduced by the purchase of property and cash outflows related to discontinued operations in the 2026 period.
Financing Activities
Net cash provided by financing activities was $5,376,000 for the nine months ended September 30, 2026, as compared to net cash provided by financing activities of $8,097,000 for the nine months ended September 30, 2025, representing a decrease of $2,721,000. During the nine months ended September 30, 2026, cash provided by financing activities primarily consisted of gross proceeds of $4,150,000 from the June 2026 private placements and net proceeds of $2,896,000 under the standby equity purchase agreement, partially offset by the repayment of a $1,200,000 promissory note and a payment of $470,000 in contingent consideration related to the MitoCareX acquisition. The decrease compared to the corresponding prior-year period was primarily attributable to the absence of proceeds from warrant exercises and promissory notes received in 2025, repayments of short-term loans in 2026, and lower net proceeds from the purchase agreement, partially offset by higher proceeds from the issuance of shares and warrants in 2026.
Item 3. Quantitative And Qualitative Disclosures About Market Risk.
We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required by this Item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Principal Executive Officer and our Principal Financial Officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our management, including each of our Principal Executive Officer and our Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. Based on such evaluation, each of our Principal Executive Officer and Principal Financial Officer has concluded that, as of September 30, 2026, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
During the period covered by this Quarterly Report, following the acquisition of MitoCareX, we included MitoCareX within our existing financial reporting and consolidation controls. The inclusion of MitoCareX did not result in changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 45 |
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially owner of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company. The Company’s property is not the subject of any pending legal proceedings.
Item 1A. Risk Factors.
We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information under this item.
Item 2. Unregistered Sales Of Equity Securities And Use Of Proceeds
Except as set forth below, there were no sales of equity securities during the period covered by this Quarterly Report that were not registered under the Securities Act and were not previously reported in a Current Report on Form 8-K filed by the Company. On August 31, 2026, pursuant to the Securities Purchase and Exchange Agreement dated February 25, 2025, as amended, entered into in connection with the acquisition of MitoCareX, the Company issued an aggregate of 6,978 shares of common stock (as adjusted to give effect to the 1-for-5 reverse stock split effected on November 9, 2026) to the former shareholders of MitoCareX upon achievement of the first milestone under such agreement. The shares were issued as contingent consideration for the acquisition, without any additional cash consideration.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosure
Not applicable.
Item 5. Other Information
During
the three months ended September 30, 2026, none of the Company’s directors or officers
| 46 |
Item 6. Exhibits.
| Exhibit | ||
| Number | Description | |
| 31.1* | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act | |
| 31.2* | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act | |
| 32.1** | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 32.2** | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 101.INS* | Inline XBRL Instance Document | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) | |
| * | Filed herewith. | |
| ** | Furnished herewith. |
| 47 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: November 16, 2026 | NEXENTIS TECHNOLOGIES INC. | |
| By: | /s/ David Palach | |
| Name: | David Palach | |
| Title: | Chief Executive Officer | |
| (Principal Executive Officer) | ||
| Date: November 16, 2026 | By: | /s/ Lital Barda |
| Name: | Lital Barda | |
| Title: | Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | ||
| 48 |